NLARx Newsletter Header
NLARx News
September 16, 2009
In This Issue
NLARx News
In the States
Outrage of the Week
Fraud & Abuse
Pharmaceuticals & Health Reform
Prices & Access
Conflicts of Interest
Patents & Generics
Advertising & Marketing
Pharma Watch
PBM Watch
Medicare & Medicaid
Reimportation
Electronic Records
Safety & Clinical Trials
Research & Development
Quick Links
Join Our Mailing List
NLARx News
SAVE THE DATE: Next NLARx Meeting November 6 in Boston More
NLARx Files Legal Brief Supporting Vermont Drug Marketing Law More
NLARx Comments to the US Trade Rep on Pharma Provisions of Korea-US Free Trade Agreement More
Consumer Groups Support PBM Transparency Amendment to H.R. 3200 More
CVS Merger Is Focus of Meeting With FTC, Union Says More
In the States
MAINE: Groups Seek Injunction Against Predatory Marketing Law More
NORTH DAKOTA: Unused Drugs Available through Pharmacy Board More
NEBRASKA: Pharmacists Forced to Serve Insurers Rather Than Patients More
TENNESSEE: State Ranks 4th Largest Consumer of Prescription Drugs More
Outrage of the Week
Inside Schering's $437 Million Tax Fraud More
Fraud and Abuse
Pfizer To Pay $2.3 Billion In Medicare/Medicaid Fraud Settlement More
It's Official: Pfizer Pleads Guilty to Illegal Marketing of Bextra More
Biovail Guilty of Illegal Kickbacks More
Pharmaceuticals and Health Reform
PhRMA Ads to Back Baucus Plan More
Why Pharma Wants Obamacare More
Baucus Includes Sunshine Act Provisions in Outline More
Waxman Seeks To Save Money On Medicare Drugs More
US Health Reforms Will Raise Prices of Breakthrough Drugs More
House Bill Would Strengthen Federal Comparative Effectiveness More
CBO Consistently Underestimates Medicare Cost Savings More
Pharma's New Aims Explain Reform Support More
Four Reform Scenarios, Four Pharma Outcomes More
Prices and Access to Health Care
Simple Arithmetic More
Double-Digit Medical Expense Trend to Continue More
Healthcare Spending on Seniors Increases over $100 Billion in 10 Years More
Comparative Effectiveness Research Remains Controversial More
Study Questions Comparative Effectiveness Savings More
Major Rollback of Drug Prices Approved by US Court of Appeals More
Is Health Spending Excessive? If So, What Can We Do About It? More
Should U.S. pursue cost-sharing deals? More
Conflicts of Interest
Ghostwriting Is Called Rife in Medical Journals More
CASPPER, GlaxoSmithKline's Friendly Ghostwriting Program More
Journals Aided in the Marketing of Gabapentin More
Medical Groups Promoted HPV Vaccine Using Drug Company Money More
Physician Groups and the Marketing of the Gardasil Vaccine More
Medtronic Defends Payments To Physicians More
Patents and Generics
Generic Drugs Create Significant Cost Savings More
GSK to Consider HIV Patent Pools for Generics in Developing Countries More
Drug Competition in Peril More
Merck Prevails in Singulair Suit More
Advertising and Marketing
Pfizer Sued Over Payments Tied to Off-Label Marketing More
Are Fines Enough to Deter Off-Label Marketing? More
The Next Marketing Frontier: Gardasil for Boys More
Lack of Knowledge Fuels Off-Label Prescribing More
Physicians Lack Knowledge of FDA Drug Use Approvals More
It's Official: Pfizer Pleads Guilty to Illegal Marketing of Bextra More
Pfizer's $2.3 Billion Promise to Behave More
Did Lexapro's Success Depend on Physician Payments? More
Document Details Plan to Promote Costly Drug More
Feds Chase Down Faulty Skincare Promos More
FDA Warns Allergan, Galderma on Marketing More
Takeda Tops In Marketing to PBMs, HMOs More
Pharma Watch
Gleevec's Lesson: Medical Success Trumps Small Market More
Eli Lilly Plans to Cut 5,500 Jobs in Overhaul  More
Roche Management: Shuffle at the Top More
Pharmaceutical Industry's Women Rank Among World's Most Powerful More
Cancer Drugs Rising to Top of Sales Pyramid  More
Antidepressants Show Upside in Economic Downturn More
Which Drug Makers Boosted Research and Development Spending the Most? More
Court Denies Schering Refund More
Lawyer Says Drugmaker Celgene Stole Her Idea More
Warner Chilcott Pays $3.1B for P&G Drug Unit  More
What the $3 Billion P&G Deal Says About the Drug Industry More
Is $1 Billion is the Right Price for Pharma M&A? More
Schering-Plough Spent $550K Lobbying the Government in the Second Quarter More
Pharma Industry Booming in Eastern Europe More
PBM Watch
Walgreen and CAT Take On Drug Prices More
Will Caterpillar-Walgreens Deal Shrink Drug Costs? More
Wellpoint Chief Calls For Reform, Defends Insurers More
PBMs Increase Lobbying As Congress Debates Healthcare Reform More
Express Scripts Spent $410,000 Lobbying in 2nd Quarter More
Consolidation For Pharmacy Management Companies Inevitable - CVS CFO More
Medco Likely Top Bidder for Aetna PBM Unit More
Express Scripts Will Weigh Options for Further Acquisitions More
Consumer Group Says Major Insurers Coerced Employees To Lobby More
Drug Stores Consider How Reform Efforts May Affect Them More
Drugs Discounted to Boost Compliance More
UnitedHealth: Stick to Your Meds, Get $20 Off Next Prescription More
Medicare and Medicaid
House Health Bill Would Cut Spending On Prescriptions for Medicare Enrollees More
House Reform Bill Contains Many Provisions Impacting Part D Sponsors and PBMs More
Medicare Drug Benefit: Lower Total Costs, But Higher Premiums More
Medicare Covers Avastin Here, But Not There More
Waxman on the Drug-Price Warpath More
Medicaid Expansions Could Spell Trouble For States, Democrats In Congress More
What the Baucus Bill Could Mean for Chantix More
Reimportation and Trade
FDA Slaps Apotex With Import Ban More
Brits Profit by Exporting Newly Cheap Drugs More
Trade Related Ruling Affects US Cotton, Prescription Drugs More
CAFTA Raises Prices, Limits Availability of Life Saving Drugs for US Trade Partners More
Electronic Records
Computer Maker Dell to Jump in Electronic Health Record Pool More
Electronic Health Records: A Focus For Big Tech Companies More
New Grant Program To Help States, Doctors With Health IT More
Online Patient Data May Open New Doors In Medical Research More
Safety and Clinical Trials
Test Paxil Case Hits Court Next Week More
Mistrial Declared in Fosamax Case More
Fosamax Users Say It Caused Jaw Injury More
Pfizer to Develop Clinical Trial Website More
Saving Your Bones: Hard Choices More
Botox Reduces Headache for Patients, Allergan More
New Blood Thinners Could Be Alternatives to Coumadin, Plavix More
Study: Aranesp Doesn't Hurt Hearts More
Evidence-Based Medicine And The Use Of Beta Blockers More
FDA Questions Broader Use of Genzyme's Clolar More
FDA Panel Backs Cancer Vaccines More
FDA Advances Merck's Gardasil for Men, Glaxo's Cervarix More
The Dark Side of Cancer Screening More
Unraveling Why Patients Don't Take Their Meds More
Research and Development
Financing of U.S. Biomedical Research and New Drug Approvals More
Global Drug Development: Europe Is Ahead More
Price Controls and New Drug Development More
Study: Lower Prices Don't Harm Innovation More